5-硫代-alpha-D-吡喃葡萄糖 | 37850-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 中文名称: 5-硫代-alpha-D-吡喃葡萄糖
• 英文名称: 5-Thio-β-D-glucopyranose
• 英文别名: 5-Thio-beta-D-glucopyranose；(2R,3R,4S,5S,6R)-6-(hydroxymethyl)thiane-2,3,4,5-tetrol
• CAS: 37850-98-9
• 化学式: C₆H₁₂O₅S
• 分子量: 196.224
• InChiKey: KNWYARBAEIMVMZ-VFUOTHLCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  126
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-thio-α-D-glucopyranosyl fluoride 在 叠氮阴离子 作用下， 以 重水 为溶剂， 生成 5-硫代-alpha-D-吡喃葡萄糖 、 5-硫代-alpha-D-吡喃葡萄糖 、 5-thio-β-D-glucopyranosyl azide 、 5-thio-α-D-glucopyranosyl azide
  参考文献：
  名称：

  5-硫代吡喃葡萄糖基碳负离子是溶剂平衡的阳离子。

  摘要：

  DOI：

  10.1021/ja017118f

文献信息

• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。
• Method for synthesis of reactive conjugate clusters
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10098959B2

  公开（公告）日：2018-10-16

  Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods.

  本文提供了改进的方法，用于合成用于这些方法的反应性共轭簇和中间体。特别是，提供了通过减少所需的合成步骤来增强反应性共轭簇合成的改进。使用改进方法制备的反应性共轭簇不包括使用现有方法形成的任何酰基转移杂质。改进的方法还提供了整体产量的增加和比现有方法更具成本效益。
• [EN] MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS OLIGOMÈRES MODIFIÉS ET LEURS UTILISATIONS
  申请人：IONIS PHARMACEUTICALS INC

  公开号：WO2021030763A1

  公开（公告）日：2021-02-18

  The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

  本公开提供了包含至少一种立体非标准核苷酸的修饰寡核苷酸的寡聚化合物。包括由12-30个连接的核苷酸组成的修饰寡核苷酸的寡聚化合物，其中修饰寡核苷酸的至少一个核苷酸是立体非标准核苷酸；且所述寡聚化合物选自RNAi化合物、修饰CRISPR化合物和人工mRNA化合物。
• THIOPYRANOSE COMPOUND AND METHOD FOR PRODUCING SAME
  申请人：FUJIFILM Corporation

  公开号：US20160355497A1

  公开（公告）日：2016-12-08

  There is provided a production method of a thiopyranose compound represented by the following Formula (2) by reacting a compound represented by the following Formula (1) with a sulfur compound. X represents a leaving group. A represents an oxygen atom or a sulfur atom. Further, each of R 1A to R 4B , R 1B to R 4B , and R 5 represents a hydrogen atom or a specific substituent.

  提供了一种通过将以下式（1）代表的化合物与硫化合物反应来制备由以下式（2）表示的硫代吡喃糖化合物的生产方法。X代表一个离去基团。A代表一个氧原子或硫原子。此外，R1A到R4B，R1B到R4B和R5分别代表氢原子或特定取代基。
• 1-Thio-D-Glucitol Derivatives
  申请人：Kakinuma Hiroyuki

  公开号：US20080132563A1

  公开（公告）日：2008-06-05

  The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

  本发明提供了以下公式的1-硫代-D-葡萄糖醇化合物，该化合物显示抑制SGLT2活性的作用，该化合物的药用可接受盐或该化合物或盐的水合物；以及包含该化合物作为活性成分的制药品，特别是用于预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的制药品。本发明还提供了制备1-硫代-D-葡萄糖醇化合物及其中间体的方法。